Mitchell R. Humphreys, MD, describes the shifting landscape of lower urinary tract symptoms (LUTS) management from a symptom-focused approach to a paradigm of altering the underlying disease progression. He focuses on changes in the medical management of nocturia and bladder outlet obstruction due to benign prostatic hyperplasia (BPH).
Read More
Jason Efstathiou, MD, DPhil, defines oligometastatic prostate cancer and the impact advanced PET/CT imaging has had on the identification of this disease state. He reviews the data deliberating on treatment tailored for these patients in both the primary high-risk and recurrent settings.
Read More
Sigrid V. Carlsson, MD, PhD, MPH, discusses the evolution of attitudes toward PSA screening for prostate cancer over time, and the importance of implementing the PSA test in a way that will truly benefit patients. She details how risk-stratifying algorithms and calculators, biomarkers, and MRI can play a role in refining prostate cancer screening.
Read More
Masoom Haider, MD, provides an overview of the current state of multiparametric MRI, especially in the setting of biopsy-naive patients with elevated PSA levels. He then describes an MRI-directed biopsy pathway and how to integrate it into prostate cancer care.
Read More
E. David Crawford, MD, reviews the findings and recommendations from the Radiographic Assessments for Detection of Advanced Recurrence (RADAR) III working group, and how its prior iterations, RADAR I and II, provided the rationale for the RADAR III manuscript. He discusses the next generation imaging modalities and radiotracers covered in RADAR III, as well as the group’s consensus on how they should be implemented in the evaluation of patients with prostate cancer.
Read More